Elevance Health stock gained 1.25 percent on October 2
Elevance Health's stock increased by 1.25 percent on October 2, 2026, reaching USD 386.43, yet remained below its 52-week high. The company reported strong Q2 2026 revenues of USD 49.83 billion, surpassing analyst expectations, and reaffirmed its full-year earnings guidance. Analysts maintain a "Buy" consensus with an average price target significantly above its current trading price.
UnitedHealth Reports on Oct. 13. Here's the 1 Number I'm Watching.
UnitedHealth Group is scheduled to report its third-quarter financial results on October 13. While investors will scrutinize revenue and earnings per share, the author emphasizes the importance of the medical care ratio, which indicates the percentage of premiums paid out for claims. This metric is crucial for assessing the insurer's profitability and will reveal if UnitedHealth maintained its efforts to lower it.
MinuteClinic is helping connect more Americans to care
MinuteClinic is expanding access to care by offering affordable and convenient in-person, virtual, and digital health options, addressing issues like long wait times and high costs. It provides services ranging from acute illness treatment and preventive care to chronic condition management and weight loss support. The initiative also aims to help close the primary care gap by offering accessible ongoing care through its clinics and virtual platforms.
Humana Inc. Research & Ratings | HUM
This article provides research and ratings for Humana Inc. (HUM), including analyst ratings, price targets, stock performance data, and financial estimates. It details the company's segments, key financial figures like EPS and dividend yield, and compares it to peers in the health insurance sector.
How Much Downside Is Left In CVS Health Stock?
CVS Health stock has fallen 12.7% in the past month, trading 22.5% below its 52-week high, despite no company-specific news. The article analyzes CVS's current financial state, noting its thin operating margins and heavy debt, which amplifies market risk. It also reviews CVS's historical performance during market shocks, particularly credit crises, where it experienced significant declines but eventually recovered.
BofA raises target for Elevance Health stock from USD 460.00 to USD 480.00
BofA Securities has increased its price target for Elevance Health (ELV) stock from USD 460.00 to USD 480.00, ahead of the company's third-quarter report. This new target is higher than the analyst consensus of USD 451.38, reflecting a positive outlook despite mixed Q2 earnings and ongoing medical-cost pressures. Elevance Health reaffirmed its fiscal 2026 adjusted earnings guidance and expects at least 12% growth in fiscal 2027.
Texas AG opens prior auth probe into Blue Cross Blue Shield of Texas
Texas Attorney General Ken Paxton has launched an investigation into Blue Cross Blue Shield of Texas (BCBSTX) regarding its prior authorization and care denial processes. The probe follows numerous reports of denied or delayed coverage for medically necessary services, including a case involving a newborn. Paxton stated that the investigation aims to determine if BCBSTX has violated Texas law, emphasizing the importance of patient care over profits.
Centene (CNC): Pricing Actions and Profit Stabilization Drive Earnings Recovery
Cambiar Opportunity Fund highlighted Centene Corporation (NYSE: CNC) as a top performer in Q2 2026, crediting pricing actions and underwriting for stabilizing profits in the healthcare sector. Despite its recovery and significant year-to-date gain, the fund notes that current earnings are still 30-50% below normalized levels. Truist also maintained a Buy rating and increased its price target for Centene.
Many 2027 Medicare plans may let members use one card for several covered benefits.
Elevance Health (NYSE: ELV) announced its affiliated health plans will offer 2027 Medicare Advantage plans designed to provide stability, choice, and more coordinated support, starting January 1, 2027. These plans will expand offerings for chronic conditions and aim to simplify benefit experiences, including the use of a single Benefits Prepaid Card for multiple covered benefits. The focus is on local needs, personalized support, and improved coordination for dual-eligible members and those managing chronic health conditions.
Elevance Health previews lower third-quarter earnings for Elevance Health stock
Elevance Health is forecasting a weaker third-quarter performance, with adjusted earnings per share projected at USD 4.72, a 21.70% decrease year-over-year. Despite this, the company raised its full-year 2026 adjusted diluted earnings per share guidance to at least USD 27 and expects to return to at least 12.00% growth in 2027. The upcoming report on October 21, 2026, will be crucial as second-half execution needs to counterbalance the current pressures, including elevated Medicaid costs.
UnitedHealth, Aetna, Humana roll out 2027 Medicare Advantage plans
UnitedHealth, Aetna, and Humana have begun rolling out their Medicare Advantage plans for the year 2027. The article, authored by Nona Tepper, was published on October 1, 2026, at 10:23 AM CDT.
Elevance Health (ELV) Is Back In The Spotlight, What Is Drawing Attention?
Elevance Health (ELV) has recently drawn attention due to its share price movement, with the stock closing at US$388.82. Despite some softer short-term trading, the company's year-to-date and one-year returns are positive. The most popular narrative suggests ELV is 14% undervalued with a fair value of $451.38, driven by the expected positive impact of AI and digital platforms on cost management and net margins.
Why home health expansions are a power play in value-based care
The article discusses how home health expansions by companies like Bayada and Addus HomeCare are strategic moves to secure value-based care contracts. These expansions are highlighted as a significant power play within the evolving landscape of healthcare.
Elevance Health's Quarterly Earnings Preview: What You Need to Know
Elevance Health (ELV) is set to release its fiscal Q3 2026 earnings, with analysts expecting an adjusted EPS of $4.72, a 21.7% decrease year-over-year, despite the company consistently beating bottom-line estimates in previous quarters. For the full fiscal year 2026, adjusted EPS is projected to decline by 10.2%, though growth is anticipated for fiscal 2027. ELV shares have outperformed the S&P 500 but lagged behind the Health Care Select Sector SPDR ETF over the past 52 weeks, with analysts generally rating the stock as a "Moderate Buy" with potential upside.
Site-neutral payments could save over $12B
A new analysis by the Employee Benefit Research Institute (EBRI) suggests that implementing site-neutral payments for certain high-cost, physician-administered drugs could save health plans and employers over $12 billion annually. These savings would result from paying hospital outpatient departments the same rates as physician offices for these medications, despite hospitals arguing for higher rates due to their complex patient care and stringent regulations. While patients may not see immediate cost-sharing relief, the overall reduction in spending could eventually lead to lower premiums for workers and their families.
Elevance Health's Quarterly Earnings Preview: What You Need to Know
Elevance Health (ELV) is set to release its fiscal Q3 2026 earnings, with analysts expecting an adjusted EPS of $4.72, a decrease from the previous year. Despite this, the company has consistently beaten Wall Street's bottom-line estimates and projects growth in fiscal 2027. Shares have outperformed the S&P 500 over the past year, and analysts maintain a "Moderate Buy" rating with a potential upside of 15.9%.
Comfort Systems USA (NYSE:FIX) Share Price Crosses Above Two Hundred Day Moving Average - Should You Sell?
Comfort Systems USA (NYSE:FIX) briefly traded above its 200-day moving average of $1,708.46, reaching $1,712.60 before settling at $1,663.68. The company reported strong Q2 earnings with EPS of $12.53 and 50.3% year-over-year revenue growth, and increased its quarterly dividend to $0.90. Despite a consensus "Buy" rating from analysts with an average target of $2,082.86, insiders have sold over $43 million in stock in the last 90 days.
Free cash flow per share of Elevance Health, Inc. – HAN:A58
This article provides financial information for Elevance Health, Inc. (HAN:A58), focusing specifically on its free cash flow per share. It indicates that the market was closed at the time of publication and no trades had occurred. The data is provided by TradingView, with market data from ICE Data Services and reference data from FactSet.
CareSource, Molina to drop ACA Marketplace plans in Ohio in 2027
CareSource and Molina Healthcare of Ohio will exit the Affordable Care Act (ACA) Marketplace in Ohio in 2027, impacting approximately 54,000 current enrollees. CareSource cited rising healthcare costs and shifts in the ACA Marketplace as reasons for its decision, while Molina Healthcare Inc. reported declining profits and higher medical care ratios in its recent earnings. Ohioans affected by this change will need to select new plans during the open enrollment period for 2027, with nine other companies approved to sell individual plans on the exchange.
8% of hospital-insurer contract disputes go public: study
A new study in Health Affairs reveals that about 8% of hospital-insurer contract relationships escalated into public disputes between 2021 and 2025, but only 2% of these actually resulted in a contract dissolution. For-profit hospitals are twice as likely to engage in "brinkmanship," publicly threatening to leave an insurer's network to secure better rates, especially when they hold significant but not overwhelming local market power. This tactic is driven by hospitals seeking higher rates to cover rising costs and offset low federal reimbursement, with researchers noting a tension between affordability for consumers and the dramatic negotiation strategies employed by providers.
ITM Power Achieves Milestone: Green Hydrogen Produced at GET H2 Nukleus - News and Statistics
ITM Power announced the successful production and delivery of green hydrogen at the GET H2 Nukleus project in Lingen, Germany, a significant milestone for the hydrogen industry. This project, a collaboration between ITM Power and Linde Engineering with RWE, demonstrates a functional large-scale hydrogen value chain in Europe, transporting green hydrogen through a 120 km pipeline to Evonik's chemical park. The facility is still undergoing commissioning as it works towards its full 200 MW commercial operation, showcasing the maturity of large-scale PEM electrolysis.
Elevance Health on Pace for Longest Losing Streak Since September 2022 -- Data Talk
Elevance Health (ELV) is currently experiencing its longest losing streak since September 2022, with the stock down for four consecutive trading days. This downturn has resulted in a 4.9% decline in stock value during this period, and it is also the first time since April that the stock has dropped for four consecutive days. Despite this recent performance, ELV has seen a 14% increase over the last 12 months.
UnitedHealth Stock Has Gone Nowhere for Five Years. Its Dividend Has Not
UnitedHealth (UNH) stock has seen minimal share price growth over the past five years, up only 3.30%, but its dividend has consistently increased since 2010, now at $9.28 annually. Despite challenges in 2025, the company projects strong operating cash flow for 2026, comfortably covering its dividend payouts. This makes UNH an attractive option for income-focused investors, especially compared to peers like Humana (HUM) which froze its dividend.
UnitedHealth Stock Has Gone Nowhere for Five Years. Its Dividend Has Not
UnitedHealth (UNH) stock has seen minimal price appreciation over the past five years, gaining only 3.30%, but its dividend has consistently increased since 2010. The company's strong operating cash flow is projected to comfortably cover its growing dividends, distinguishing it from peers like Humana which froze its payout. Despite recent challenges like soaring medical costs and negative Medicaid margins, UNH's consistent dividend growth makes it an attractive holding for income-focused investors.
Centene Corporation (CNC) Stock Price, News, Quote & History
This Yahoo Finance page provides a comprehensive overview of Centene Corporation (CNC), including its current stock price, recent news, and historical performance. As of September 29, 2026, CNC's stock closed at $62.21, with various news articles discussing its growth prospects, financial health, and comparisons to peers. The performance overview highlights significant year-to-date and 1-year gains, outperforming the S&P 500.
Elevance Health stock keeps guidance as Q3 earnings run ahead
Elevance Health has reiterated its 2026 adjusted EPS guidance of at least USD 27.00, despite third-quarter adjusted earnings tracking ahead of expectations. This continued guidance emphasizes the company's strong earnings execution and medical cost control. Elevance Health also reported Q2 adjusted EPS of USD 7.45, surpassing the consensus estimate, with the next earnings report scheduled for October 21, 2026.
Centene Corporation (CNC) options chain
This article from Yahoo Finance provides the options chain for Centene Corporation (CNC), detailing its stock performance and available options data. It lists the current stock price, recent trading activity, and indicates that there are no calls or puts currently available for the specified strike prices. The article also includes related tickers in the healthcare sector.
Elevance Health stock last trades at USD 393.56 on September 28, 2026
Elevance Health stock last traded at USD 393.56 on September 28, 2026, marking a 0.64 percent decrease from its previous close. The company reaffirmed its 2026 adjusted earnings guidance of at least USD 27.00 per diluted share in a September 10 filing. Elevance Health also maintained its full-year benefit expense ratio guidance of 90.20 percent plus or minus 50 basis points.
Elevance Health stock weighs a raised EPS outlook
Elevance Health's stock is being evaluated after the company raised its 2026 adjusted EPS guidance to at least $27.00 per share, surpassing analyst consensus. This updated outlook follows a strong second quarter, despite mixed operating results including improved Medicare Advantage performance and continued pressure on Medicaid. The stock closed at $396.09 on September 25, 2026, balancing positive guidance against ongoing medical-cost and Medicaid risks.
New analysis points finger at payers for IDR problems
A new analysis from specialty medical societies contends that payers are largely responsible for problems with the No Surprises Act's independent dispute resolution (IDR) process. The report suggests that payers frequently lose disputes due to non-participation or procedural failures, and often submit unreasonably low offers, contradicting their complaints about high provider win rates. The groups shared their findings with Congress, urging enforcement of payer obligations and allowing recent IDR process changes to take effect before implementing blanket reforms.
Elevance Health stock heads into the open after a 0.8 percent gain
Elevance Health stock gained 0.8 percent on September 24, 2026, closing at USD 398.00 on the NYSE, outperforming the S&P 500 which fell 0.02 percent. The company has also scheduled a quarterly dividend payment of USD 1.72 per share for September 25, 2026, with an ex-dividend date of September 10, 2026. This performance follows market trends described by CNBC, with healthcare stocks generally performing well.
Danaher Corporation (DHR) stock price, news, quote and history - Yahoo Finance
This Yahoo Finance page provides a summary of Danaher Corporation (DHR) stock information, including its current price, market status, and a compilation of recent news articles from various financial outlets. The news highlights analyses of DHR's valuation, growth prospects in biotechnology and label-free detection, and comparisons with other healthcare stocks like Cardinal Health and Medtronic. It also touches upon factors influencing its stock performance, such as dividend reaffirmation and segment strength.
Five Texas Hospitals Tied to HCA Sue Independence Blue Cross Over $345,000 in Denied Claims, Including Emergency Care
Five HCA-affiliated hospitals in Texas have sued Independence Blue Cross, a Philadelphia-based insurer, over $345,000 in allegedly denied or underpaid claims for eight members, including emergency care. The lawsuit claims the insurer violated federal and state law by requiring prior authorization for emergency services and failing to provide specific clinical reasons for denials. This dispute highlights ongoing issues within the BlueCard Program regarding varying authorization rules and medical necessity standards across different Blue Cross Blue Shield plans.
Elevance Health stock carries a USD 27 adjusted EPS outlook
Elevance Health's stock is currently trading below its 52-week high, but the company has reaffirmed a strong adjusted EPS outlook of at least USD 27 per diluted share for 2026. This guidance, along with better-than-expected Q2 2026 financial results, provides a clear earnings anchor for investors. The medical-cost ratio remains a critical operating variable to monitor due to potential impacts on earnings conversion.
AM Best withdraws ratings of Elevance Health's Hawaii captive
AM Best has affirmed and then withdrawn the credit ratings of WellPoint Insurance Services, Inc., the Hawaii-domiciled captive of Elevance Health, at the company's request. The ratings, which included an 'A- (Excellent)' Financial Strength Rating and 'a- (Excellent)' Long-Term Issuer Credit Rating with a stable outlook, were withdrawn because the company no longer wishes to participate in AM Best's interactive rating process. The ratings reflect the captive's adequate balance sheet strength, operating performance, and appropriate enterprise risk management, supported by continued capital growth and parent company flexibility.
Elevance Health stock heads into the open after a 0.45 percent drop
Elevance Health stock experienced a 0.45 percent drop, closing at USD 400.63 on September 23, 2026, while the S&P 500 also fell by 0.8 percent. The stock traded within a 52-week range of USD 274.84 to USD 436.24. The company has a scheduled cash dividend payment of USD 1.72 per share on September 25, 2026.
Did UnitedHealth Name The Fix Before Its Stock Ran?
UnitedHealth Group (UNH) stock has significantly risen since March 2026, following the company's previously announced strategy to improve margins by exiting less managed plans and narrowing Medicare Advantage networks. The company's adjusted earnings per share have increased, and it raised its full-year 2026 adjusted earnings outlook, indicating the success of its planned adjustments and cost reductions. However, the commercial book's margin recovery is still projected to extend beyond 2027, suggesting ongoing areas for improvement.
Elevance Health stock gains 2.1 percent on September 22
Elevance Health's stock closed up 2.1 percent at $347.84 on September 22, 2026, on the NYSE. The company reported quarterly revenue of $49.83 billion and earnings per share of $7.45, exceeding consensus estimates. Elevance Health also raised its full-year 2026 adjusted diluted EPS guidance to at least $26.75.
Top 10: Chief Digital Officers in Healthcare
This article lists the top 10 Chief Digital Officers (CDOs) in the healthcare industry, ranked by the revenue of their respective organizations. These executives, from companies like Cigna, Roche, and Vertex, are driving digital transformation, AI adoption, and data strategies to modernize patient experience and drug development. The list highlights their significant roles in an evolving technological landscape within healthcare.
Cerenome Secures In-Network Agreement with Blue Cross Blue Shield of Michigan, Expanding CNSide® Contracted Coverage to Approximately 158 Million Covered Lives
Cerenome, through its subsidiary CNSide Diagnostics, LLC, has secured an in-network provider agreement with Blue Cross Blue Shield of Michigan (BCBSM) for its CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay. This agreement expands CNSide's contracted coverage to approximately 158 million commercial and Medicare Advantage covered lives, significantly strengthening its national reimbursement platform. The CNSide® CSF Assay Platform is crucial for rapid diagnoses, treatment monitoring, and guidance for patients with leptomeningeal metastases.
Elevance Health stock heads into the open after a 2.1 percent gain
Elevance Health stock experienced a 2.1 percent gain on the NYSE, closing at USD 347.84 on September 22, 2026. This performance outpaced the broader US market, with the S&P 500 rising only 0.3 percent on the same day. The stock traded within a range of USD 340.00 to USD 350.00, and its next quarterly results are anticipated on October 21, 2026.
Elevance Health stock holds near its yearly high
Elevance Health stock traded at USD 407.38 on September 22, 2026, remaining near its 52-week high of USD 433.54 but significantly above its low of USD 273.76. The company's Carelon segment reported a 7.1% increase in revenue to USD 37.2 billion in the first half of 2026, providing a key operational reference for investors. This performance positions Elevance Health at a demanding point in its annual range, with the current price 6.0% below its high.
How Centene's Strong Cash Flow Is Reshaping Its Balance Sheet
Centene's strong operating cash flow, including nearly $8 billion in the first half of 2026, is allowing the company to significantly improve its balance sheet. The insurer is reducing debt by repurchasing senior notes and leveraging receivables, driving its debt-to-capital ratio down to 41.6%. This financial flexibility is crucial as Centene navigates payment timing swings and a dynamic healthcare environment.
UnitedHealth Group stock ends the day little changed at the close
UnitedHealth Group (UNH) stock closed slightly up by 0.18% at USD 377.56 on September 21, 2026, performing resiliently compared to the broader S&P 500's decline. The stock traded roughly 4.6 million shares, and investors are now looking forward to the next earnings report scheduled for October 13, 2026. After-hours trading saw the shares modestly higher.
Elevance Health (ELV) Stock May Be Below Fair Value As Guidance Was Reaffirmed
Elevance Health (ELV) stock has seen a significant 33.6% gain over the past year, prompting investors to assess its current valuation. Despite the impressive performance, the stock trades at a P/E ratio of 18.0x, which is a discount compared to the broader Healthcare sector (24.0x) and its peer group (26.8x). This suggests potential undervaluation, especially as management recently reaffirmed its 2026 earnings and cost guidance, signaling confidence in future profitability.
Medical debt impacts 1 in 3 insured adults
A new survey reveals that one-third of privately insured adults under 65 are burdened by medical debt, with nearly half owing $2,000 or more. This debt often stems from hospital services and even routine care, leading to significant stress and financial strain, causing many to delay necessary healthcare or cut back on basic necessities. The findings highlight a critical failure in the healthcare system, with respondents blaming insurance companies and the broader system, and favoring solutions like interest-free payment plans and financial assistance.
Can Carelon Drive Elevance Health's Future Earnings Growth?
Carelon, a segment of Elevance Health (ELV), is becoming a crucial driver for the company's long-term growth by expanding beyond traditional health insurance into integrated care delivery, pharmacy, and care management. Despite a first-quarter operating gain decline due to membership issues and investments, its capabilities in improving clinical outcomes and operational efficiency position it for future success. This growth complements Elevance Health's overall financial momentum and competitive standing against rivals like UnitedHealth Group and Humana, even as its stock performance and valuation show mixed signals.
Spotlight On Three Promising Penny Stocks In September 2026
This article identifies three promising penny stocks—Solowin Holdings (AXG), CuriosityStream (CURI), and Clover Health Investments (CLOV)—for September 2026, highlighting their financial health and market potential. Solowin Holdings is an investment holding company in fintech with significant revenue growth, while CuriosityStream, a media and entertainment company, has turned profitable and is trading below its fair value. Clover Health Investments, an insurance provider, has improved its financial performance and has no debt, though it has seen insider selling.
Elevance Health Inc. stock underperforms Wednesday when compared to competitors
Elevance Health Inc. (ELV) shares fell 1.19% to $412.56 on Wednesday, underperforming the broader market as the S&P 500 and Dow Jones Industrial Average also declined. This marked the second consecutive day of losses for the stock. The market-wide downturn contributed to the underperformance of Elevance Health Inc. compared to its competitors.
Are Medical Stocks Lagging Elevance Health, Inc. (ELV) This Year?
Elevance Health (ELV) and American Well Corporation (AMWL) are two medical stocks that have significantly outperformed the broader Medical sector and their respective industries this year. Elevance Health has returned 19.1% year-to-date, while American Well Corporation has seen an impressive 178.4% return, both holding a Zacks Rank #2 (Buy). Investors are advised to keep an eye on these companies for continued strong performance.
